ArticlesCompany Highlights
June 3, 2024

Treatment for multiple sclerosis: bile acid supplementation prevents polarization of astrocytes and microglia to neurotoxic phenotypes

Multiple sclerosis (MS) is a non-contagious autoimmune neurological disease of the central nervous system. MS is a degenerative disease affecting the psychological and physical conditions of the patients, as well as both...

ArticlesCompany Highlights
May 7, 2024

How diet affects the gut microbiome and its implications for diseases

The interplay between diet, the gut microbiome, and host health is cryptic. Diet can influence microbiome and microbiome can affect disease development.[1] The gut flora includes: Pathological imbalance in...

ArticlesCompany Highlights

The role of bile acid as excipients in drug delivery

Bile salts include a large family of amphiphilic steroids with 4 or 5 rings, derived, by the liver, from cholesterol with very unique physical-chemical (and biological) characteristics.  Compared to...

Company HighlightsEvent
April 5, 2024

CPHI Japan 2024 – Tokyo

ICE Pharma will be attending CPHI Japan 2024 which will take place in Tokyo from April 17th to 19th. CPhI Japan is a prominent trade fair in the pharmaceutical...

Company HighlightsEvent
March 15, 2024

DCAT Week 2024 – Kick off

Excited to kick off DCAT week alongside our ICE Pharma team, you’re all set to dive in! At ICE Pharma, we offer best-in-class products for the pharmaceutical industry, manufacturing a diverse...

Company HighlightsEvent
February 22, 2024

DCAT Week 2024

ICE Pharma is happy to announce our participation in DCAT Week 2024! DCAT Week is the premier global event held each year in New York City for companies engaged...

ArticlesCompany Highlights
February 1, 2024

Lithocholic acid (LCA) is enriched in the microbiome of centenarians

The centenarian’s riddle explores the keys to longevity.  Many scientists estimate longevity is based 20% on genetics, with 80% determined by your lifestyle choices and environment, but for some...

ArticlesCompany Highlights
January 10, 2024

Ursodeoxycholic acid improves outcomes in liver diseases

Chronic liver disease (CLD) is one of the leading causes of disability-adjusted life years (DALYs) in the total population. The global burden of CLD is increasing globally. Although screening,...

ArticlesCompany Highlights
January 5, 2024

The potential of bile acids as anti-COVID-19 therapies

Professor Stefano Fiorucci, member of ICE Pharma’s Scientific Advisory Board, and his colleagues, examined how the potential of bile acids as anti-COVID-19 therapies. Preventing SARS-CoV-2 infection by modulating viral host...

Company HighlightsEvent
December 4, 2023

ICE Pharma attended CPHI India 2023

ICE Pharma attended the main pharma industry exhibition Southeast Asia, CPHI India, which was held in Delhi from 28 – 30 of November. We would like to thank our...

Company HighlightsInsights
November 17, 2023

Bile acids – Thyroid hormone activation

Bile acids are important metabolic messengers. Modifications in BA abundance or signalling are associated with metabolic diseases including obesity, type 2diabetes, non-alcoholic steatohepatitis and atherosclerosis. Bile acids have long...

Company HighlightsEvent
November 2, 2023

ICE Pharma attended CPHI Barcelona 2023

ICE Pharma attended the main pharma industry exhibition of 2023, CPHI, which was held in Barcelona from 24 to 26 of October. During the three days event, we had...